Get the Stockscreener App
25.46
0.04%
+0.01
After Hours:
25.46
Deciphera Pharmaceuticals Inc stock is currently priced at $25.46, with a 24-hour trading volume of 1.15M.
It has seen a +0.04% increased in the last 24 hours and a +72.96% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $25.45 pivot point. If it approaches the $25.46 resistance level, significant changes may occur.
Previous Close:
$25.45
Open:
$25.46
24h Volume:
1.15M
Market Cap:
$2.20B
Revenue:
$163.36M
Net Income/Loss:
$-194.94M
P/E Ratio:
-10.83
EPS:
-2.35
Net Cash Flow:
$-147.48M
1W Performance:
+0.39%
1M Performance:
+72.96%
6M Performance:
+109.38%
1Y Performance:
+84.49%
1D Range:
$25.44
$25.47
52W Range:
$9.90
$25.55
Deciphera Pharmaceuticals Inc Stock (DCPH) Company Profile
Name
Deciphera Pharmaceuticals Inc
Sector
Phone
781-209-6400
Address
500 Totten Pond Road, 6th Floor, Waltham, MA
Deciphera Pharmaceuticals Inc Stock (DCPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-30-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-10-23 | Upgrade | Stifel | Hold → Buy |
| Jan-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-29-22 | Initiated | Cowen | Outperform |
| Aug-05-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-28-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-08-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-08-21 | Downgrade | Stifel | Buy → Hold |
| Nov-05-21 | Downgrade | Truist | Buy → Hold |
| Sep-30-21 | Resumed | Stifel | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| May-07-20 | Downgrade | Nomura | Buy → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Dec-20-19 | Reiterated | Jefferies | Buy |
| Oct-29-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Oct-22-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Sep-30-19 | Initiated | Jefferies | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Dec-31-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-25-18 | Initiated | Leerink Partners | Underperform |
| Aug-29-18 | Initiated | Raymond James | Outperform |
| Jul-05-18 | Initiated | SunTrust | Buy |
| Jun-19-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-16-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-23-17 | Initiated | JP Morgan | Overweight |
| Oct-23-17 | Initiated | Nomura | Buy |
| Oct-23-17 | Initiated | Piper Jaffray | Overweight |
View All
Deciphera Pharmaceuticals Inc Stock (DCPH) Latest News
New York State Common Retirement Fund Has $383000 Stock Position in Deciphera Pharmaceuticals, Inc. (NASDAQ ... - Defense World
Defense World
Can Deciphera Pharmaceuticals, Inc. (DCPH) Climb 79% to Reach the Level Wall Street Analysts Expect? - Yahoo Movies Canada
Yahoo Movies Canada
Deciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading Volume - MarketBeat
MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Squarespace, Inc ... - Morningstar
Morningstar
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Squarespace, Inc ... - GlobeNewswire
GlobeNewswire
Is the Options Market Predicting a Spike in Deciphera (DCPH) Stock? - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Deciphera Pharmaceuticals Inc Stock (DCPH) Financials Data
Deciphera Pharmaceuticals Inc (DCPH) Revenue 2024
DCPH reported a revenue (TTM) of $163.36 million for the quarter ending December 31, 2023, a +21.87% rise year-over-year.
Deciphera Pharmaceuticals Inc (DCPH) Net Income 2024
DCPH net income (TTM) was -$194.94 million for the quarter ending December 31, 2023, a -8.95% decrease year-over-year.
Deciphera Pharmaceuticals Inc (DCPH) Cash Flow 2024
DCPH recorded a free cash flow (TTM) of -$147.47 million for the quarter ending December 31, 2023, a +4.05% increase year-over-year.
Deciphera Pharmaceuticals Inc (DCPH) Earnings per Share 2024
DCPH earnings per share (TTM) was -$2.29 for the quarter ending December 31, 2023, a +10.20% growth year-over-year.
Deciphera Pharmaceuticals Inc Stock (DCPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kelly Thomas Patrick | Chief Financial Officer |
Feb 16 '24 |
Sale |
15.62 |
3,010 |
47,009 |
80,350 |
| Sherman Matthew L | EVP & Chief Medical Officer |
Feb 16 '24 |
Sale |
15.62 |
2,615 |
40,840 |
108,739 |
| Pitman Jama | SVP, Chief Development Officer |
Feb 16 '24 |
Sale |
15.62 |
2,267 |
35,405 |
68,031 |
| Martin Daniel C. | Chief Commercial Officer |
Feb 16 '24 |
Sale |
15.62 |
2,267 |
35,405 |
55,118 |
| Kelly Thomas Patrick | Chief Financial Officer |
Jan 16 '24 |
Sale |
14.47 |
2,435 |
35,234 |
66,085 |
| Sherman Matthew L | EVP & Chief Medical Officer |
Jan 16 '24 |
Sale |
14.47 |
2,435 |
35,234 |
94,079 |
| Pitman Jama | SVP, Chief Development Officer |
Jan 16 '24 |
Sale |
14.47 |
1,624 |
23,499 |
50,573 |
| Martin Daniel C. | Chief Commercial Officer |
Jan 16 '24 |
Sale |
14.47 |
1,624 |
23,499 |
47,660 |
| Hoerter Steven L. | President and CEO |
Dec 13 '23 |
Sale |
15.37 |
30,664 |
471,217 |
72,763 |
| Kelly Thomas Patrick | Chief Financial Officer |
Dec 13 '23 |
Sale |
15.37 |
2,792 |
42,905 |
68,520 |
About Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
2.30%
1.24%
Cap:
|
Volume (24h):